Gradient plate method to induce Streptococcus pyogenes resistance

被引:11
作者
Carsenti-Etesse, H
Roger, PM
Dunais, B
Durgeat, S
Mancini, G
Bensoussan, M
Dellamonica, P
机构
[1] Univ Hosp, F-06202 Nice 3, France
[2] Takeda Lab, F-92816 Puteaux, France
关键词
D O I
10.1093/jac/44.4.439
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In recent years, increasing numbers of Streptococcus pyogenes (GAS) strains displaying resistance to macrolides have been reported in Finland, Japan, Asia and Spain. Antibiotic use has been shown to be a risk factor for infection with and carriage of drug-resistant streptococci. The aim of this study was to compare in-vitro development of resistance of streptococci to beta-lactams (penicillin, amoxycillin, cefotiam and cefuroxime) and erythromycin by serial passages in subinhibitory concentrations of antibiotics (subMICs) by gradient plate method. Three clinical strains of GAS were tested. Two were susceptible to erythromycin (MIC = 0.015 mg/L and 0.013 mg/L) and one resistant. Serial passages were performed daily by gradient plate method until a four-fold increase of the MIC was achieved. GAS variants obtained after serial passages in beta-lactams had MICs increased at least four-fold. They remained susceptible to these antibiotics. With erythromycin, final MICs reached intermediate and resistant level. Results obtained in this study with erythromycin are in good correlation with clinical studies showing that prior exposure to macrolides may help to facilitate the emergence of drug-resistant strains of streptococci.
引用
收藏
页码:439 / 443
页数:5
相关论文
共 24 条
[1]   IN-VITRO ACTIVITIES OF 22-BETA-LACTAM ANTIBIOTICS AGAINST PENICILLIN-RESISTANT AND PENICILLIN-SUSCEPTIBLE VIRIDANS GROUP STREPTOCOCCI ISOLATED FROM BLOOD [J].
ALCAIDE, F ;
LINARES, J ;
PALLARES, R ;
CARRATALA, J ;
BENITEZ, MA ;
GUDIOL, F ;
MARTIN, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2243-2247
[2]  
ALCAIDE F, 1995, 35 INT C ANT AG CHEM, P94
[3]  
BEGOVAC J, 1990, LANCET, V335, P109
[4]   In vitro development of resistance of Streptococcus pneumoniae to beta-lactam antibiotics [J].
CarsentiEtesse, H ;
Durant, J ;
DeSalvador, F ;
Bensoussan, M ;
Bensoussan, F ;
Pradier, C ;
Thabaut, A ;
Dellamonica, P .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1995, 1 (01) :85-94
[5]   In vitro selection of Streptococcus pneumoniae strains with decreased susceptibility to beta-lactams and macrolides [J].
CarsentiEtesse, H ;
Roger, PM ;
Dunais, B ;
Mancini, G ;
Thabaut, A ;
Dellamonica, P .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (10) :735-746
[6]   Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes [J].
Clancy, J ;
Petitpas, J ;
DibHajj, F ;
Yuan, W ;
Cronan, M ;
Kamath, AV ;
Bergeron, J ;
Retsema, JA .
MOLECULAR MICROBIOLOGY, 1996, 22 (05) :867-879
[7]  
*COM ANT SOC FRANC, 1988, PATHOL BIOL, V46, P1
[8]   Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995 [J].
Cornaglia, G ;
Ligozzi, M ;
Mazzariol, A ;
Valentini, M ;
Orefici, G ;
Fontana, R .
EMERGING INFECTIOUS DISEASES, 1996, 2 (04) :339-342
[9]   Why have group A streptococci remained susceptible to penicillin? Report on a symposium [J].
Horn, DL ;
Zabriskie, JB ;
Austrian, R ;
Cleary, PP ;
Ferretti, JJ ;
Fischetti, VA ;
Gotschlich, E ;
Kaplan, EL ;
McCarty, M ;
Opal, SM ;
Roberts, RB ;
Tomasz, A ;
Wachtfogel, Y .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) :1341-1345
[10]  
JARVINEN H, 1989, LANCET, V1, P1022